BiotechTube
Aucta Pharmaceuticals

Aucta Pharmaceuticals

Pre-clinical
Piscataway, United StatesFounded 2014auctapharma.com

Aucta Pharmaceuticals is a private, US-based specialty pharma company with a dual-site R&D and manufacturing presence in New Jersey and Shanghai. Its strategy centers on using its proprietary AucPed, AucTrol, and AucMist technology platforms to create differentiated dosage forms of established drugs, aiming to improve patient adherence and outcomes. The company is backed by a consortium of global and China-based healthcare investors and is advancing a pipeline focused on CNS and orphan diseases.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Total funding raised: $35M

AI Company Overview

Aucta Pharmaceuticals is a private, US-based specialty pharma company with a dual-site R&D and manufacturing presence in New Jersey and Shanghai. Its strategy centers on using its proprietary AucPed, AucTrol, and AucMist technology platforms to create differentiated dosage forms of established drugs, aiming to improve patient adherence and outcomes. The company is backed by a consortium of global and China-based healthcare investors and is advancing a pipeline focused on CNS and orphan diseases.

Central Nervous System (CNS) DisordersMetabolic DiseasesOrphan and Specialty IndicationsOphthalmicsDermatologyPediatrics

Technology Platform

Aucta's core technology consists of three proprietary platforms: AucPed™ for pediatric formulations, AucTrol™ for controlled-release oral technologies, and AucMist™ for nasal drug delivery, enabling the creation of differentiated dosage forms from proven molecules.

Funding History

4
Total raised:$35M
Series A$12MJun 15, 2021
Series A$15MJun 15, 2020
Seed$3MJun 15, 2019
Seed$5MJun 15, 2018

Opportunities

The 505(b)(2) pathway offers a large addressable market by improving upon existing drugs in multi-billion dollar therapeutic areas like CNS.
There is significant growth potential in developing pediatric formulations and in leveraging the dual US-China operational model to commercialize products in both major pharmaceutical markets.

Risk Factors

Key risks include regulatory hurdles for 505(b)(2) approvals, commercial competition from originator drugs and generics, execution challenges in managing a dual-country operation, and pipeline dependency on a limited number of lead assets.

Competitive Landscape

Aucta competes with other specialty pharma companies focused on product lifecycle management (e.g., Supernus, Azurity) and generic manufacturers. Its differentiation lies in its proprietary formulation platforms (AucPed, AucTrol, AucMist) and integrated R&D/manufacturing capabilities in both the US and China.